June 10, 2009
Submitted by art on Thu, 2009-06-11 07:56.
These market analysts are reporting that: The Multiple Sclerosis (MS) Market Has Total Global Revenues of Over $6bn in 2008. It Will Exceed $9bn During the Second Half of Next Decade.
I report this because the "good" side of this is that it means MS drugs can be very lucrative. Which means that pharma and biotech companies will consider MS as a target disease for their products. For the most part, more attention is better.